Moreover, it has also been suggested that relaxin-2 could predict the severity of cardiovascular events in CHF patients within 180 days after discharge [98], and the combined assessment of relaxin-2 and BNP had a remarkable potential application in clinical daily practice, improving the sensitivity and specificity of diagnosis for decompensated CHF when compared with assaying BNP alone [99]. The gene discussed is NPPB; the disease is congestive heart failure.